Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 2
2000 2
2002 1
2003 5
2004 2
2005 5
2006 5
2007 6
2008 4
2009 2
2010 2
2011 3
2012 4
2013 7
2014 11
2015 14
2016 11
2017 7
2018 18
2019 23
2020 25
2021 32
2022 39
2023 29
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. Newsome SD, et al. Neurol Ther. 2023 Dec;12(6):1909-1935. doi: 10.1007/s40120-023-00549-7. Epub 2023 Oct 11. Neurol Ther. 2023. PMID: 37819598 Free PMC article. Review.
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of alternative outcomes and biomarkers, to broaden the clinical information captured by NEDA. ...One such outcome is the set of criteria …
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of a …
Revisiting the Time Needed to Provide Adult Primary Care.
Porter J, Boyd C, Skandari MR, Laiteerapong N. Porter J, et al. J Gen Intern Med. 2023 Jan;38(1):147-155. doi: 10.1007/s11606-022-07707-x. Epub 2022 Jul 1. J Gen Intern Med. 2023. PMID: 35776372 Free PMC article.
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, Shubin R, Wray S, Weiss MS, Bosco JA, Power SA, Mok K, Inglese M. Fox E, et al. Mult Scler. 2021 Mar;27(3):420-429. doi: 10.1177/1352458520918375. Epub 2020 Apr 30. Mult Scler. 2021. PMID: 32351164 Free PMC article. Clinical Trial.
The primary endpoint was B-cell depletion. RESULTS: In all cohorts (N = 48), median B-cell depletion was >99% by week 4, maintained at weeks 24 and 48. ...Overall, 74% of patients had no evidence of disease activity (NEDA). CONCLUSION: Ublituximab was safely infu …
The primary endpoint was B-cell depletion. RESULTS: In all cohorts (N = 48), median B-cell depletion was >99% by week 4, maintaine …
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P. Giovannoni G, et al. Mult Scler. 2022 Jul;28(8):1219-1228. doi: 10.1177/13524585211049392. Epub 2021 Oct 12. Mult Scler. 2022. PMID: 34634968 Free PMC article.
BACKGROUND: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment. ...METHODS: Between CLARITY and CLARITY Extension, patients transitioned from cladribine tablets 3.5 mg/kg to placebo (CP3.5 gro …
BACKGROUND: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis …
Functional Networks in Epilepsy Presurgical Evaluation.
Foit NA, Bernasconi A, Bernasconi N. Foit NA, et al. Neurosurg Clin N Am. 2020 Jul;31(3):395-405. doi: 10.1016/j.nec.2020.03.004. Epub 2020 Apr 23. Neurosurg Clin N Am. 2020. PMID: 32475488 Review.
Neuroimaging genomics in psychiatry-a translational approach.
Mufford MS, Stein DJ, Dalvie S, Groenewold NA, Thompson PM, Jahanshad N. Mufford MS, et al. Genome Med. 2017 Nov 27;9(1):102. doi: 10.1186/s13073-017-0496-z. Genome Med. 2017. PMID: 29179742 Free PMC article. Review.
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
Gonzalez-Martinez A, Patel R, Healy BC, Lokhande H, Paul A, Saxena S, Polgar-Turcsanyi M, Weiner HL, Chitnis T. Gonzalez-Martinez A, et al. J Neuroinflammation. 2023 May 30;20(1):131. doi: 10.1186/s12974-023-02811-z. J Neuroinflammation. 2023. PMID: 37254147 Free PMC article.
We found that 548a-3p serum levels were higher levels in fingolimod-treated patients classified as NEDA-3, compared to the EDA-3 group in both the Discovery (n = 31; p = 0.04) and Validation (n = 22; p = 0.03) cohorts 6 months after treatment initiation; miR- …
We found that 548a-3p serum levels were higher levels in fingolimod-treated patients classified as NEDA-3, compared to the EDA-3 grou …
Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)-Data From a Local Norwegian Cohort.
Jaklin AK, Benjaminsen E, Alstadhaug KB. Jaklin AK, et al. Front Neurol. 2021 Oct 20;12:765837. doi: 10.3389/fneur.2021.765837. eCollection 2021. Front Neurol. 2021. PMID: 34744991 Free PMC article.
Three patients experienced rebound in the wake of discontinuation (7.5%). Of the patients receiving NTZ for more than 3 years (n = 33), 50% had achieved NEDA-3 after 3 years. Compared to those with evidence of disease activity (EDA), these NEDA-3 patients had …
Three patients experienced rebound in the wake of discontinuation (7.5%). Of the patients receiving NTZ for more than 3 years (n = 33 …
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. Havrdová E, et al. Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar. Mult Scler J Exp Transl Clin. 2018. PMID: 29568544 Free PMC article.
OBJECTIVE: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. METHODS: NEDA was assessed in a modified intent-to-treat population (n = 1520) from the pooled …
OBJECTIVE: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictiv …
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P, Oreja-Guevara C, Siva A, Van Wijmeersch B, Wiendl H, Wuerfel J, Buffels R, Kadner K, Kuenzel T, Comi G; CASTING Investigators. Vermersch P, et al. Eur J Neurol. 2022 Mar;29(3):790-801. doi: 10.1111/ene.15171. Epub 2021 Nov 25. Eur J Neurol. 2022. PMID: 34748672 Free PMC article. Clinical Trial.
NEDA across subgroups was highest in patients with a baseline EDSS score <2.5 (77.2% [95% CI 72.8-81.2], n/N = 315/408). NEDA was higher in patients receiving one prior DMT (77.6% [95% CI 73.2-81.6], n/N = 312/402) versus two prior DMT …
NEDA across subgroups was highest in patients with a baseline EDSS score <2.5 (77.2% [95% CI 72.8-81.2], n/N = 315/4 …
228 results